Korea Investment CORP acquired a new position in shares of Editas Medicine Inc (NASDAQ:EDIT) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 61,300 shares of the company’s stock, valued at approximately $2,196,000. Korea Investment CORP owned about 0.13% of Editas Medicine as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of EDIT. Wells Fargo & Company MN grew its holdings in Editas Medicine by 16.1% during the 1st quarter. Wells Fargo & Company MN now owns 56,653 shares of the company’s stock worth $1,878,000 after acquiring an additional 7,862 shares during the last quarter. SG Americas Securities LLC bought a new stake in Editas Medicine during the 1st quarter worth about $332,000. DekaBank Deutsche Girozentrale grew its holdings in Editas Medicine by 252.7% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 26,100 shares of the company’s stock worth $852,000 after acquiring an additional 18,700 shares during the last quarter. Victory Capital Management Inc. grew its holdings in Editas Medicine by 12.4% during the 1st quarter. Victory Capital Management Inc. now owns 50,292 shares of the company’s stock worth $1,667,000 after acquiring an additional 5,560 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System grew its holdings in Editas Medicine by 28.5% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 15,768 shares of the company’s stock worth $523,000 after acquiring an additional 3,496 shares during the last quarter. 67.22% of the stock is currently owned by hedge funds and other institutional investors.

Editas Medicine stock opened at $32.41 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 14.50 and a quick ratio of 14.50. Editas Medicine Inc has a 1 year low of $19.06 and a 1 year high of $45.02.

Editas Medicine (NASDAQ:EDIT) last released its earnings results on Monday, August 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.15). Editas Medicine had a negative net margin of 623.35% and a negative return on equity of 61.27%. The business had revenue of $7.37 million for the quarter, compared to analyst estimates of $7.01 million. During the same quarter in the previous year, the company posted ($0.65) earnings per share. The business’s revenue for the quarter was up 137.7% on a year-over-year basis. analysts expect that Editas Medicine Inc will post -3 earnings per share for the current year.

In other Editas Medicine news, CEO Katrine Bosley sold 12,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $32.35, for a total transaction of $388,200.00. Following the transaction, the chief executive officer now directly owns 1,254,179 shares in the company, valued at approximately $40,572,690.65. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Vickesh Myer sold 14,000 shares of the company’s stock in a transaction dated Tuesday, June 19th. The shares were sold at an average price of $38.26, for a total transaction of $535,640.00. Following the transaction, the insider now owns 4,300 shares in the company, valued at $164,518. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 85,666 shares of company stock worth $2,864,075. Corporate insiders own 5.20% of the company’s stock.

A number of brokerages have commented on EDIT. BidaskClub raised shares of Editas Medicine from a “sell” rating to a “hold” rating in a report on Tuesday, August 21st. ValuEngine raised shares of Editas Medicine from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. JPMorgan Chase & Co. set a $36.00 price objective on shares of Editas Medicine and gave the stock a “hold” rating in a report on Monday, August 6th. Finally, Zacks Investment Research lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a report on Thursday, August 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have issued a buy rating to the stock. Editas Medicine has a consensus rating of “Buy” and an average target price of $47.43.

About Editas Medicine

Editas Medicine, Inc operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments.

Read More: What does earnings per share mean?

Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine Inc (NASDAQ:EDIT).

Institutional Ownership by Quarter for Editas Medicine (NASDAQ:EDIT)

Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.